Pure Communications Release: Ember Therapeutics Secures Exclusive License to Key Brown Fat Technology and Intellectual Property from the Joslin Diabetes Center

Published: Mar 28, 2012

BOSTON--(BUSINESS WIRE)--Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development. Research on this BMP7 technology was led by Yu-Hua Tseng, Ph.D., Aaron Cypess, M.D., Ph.D., and C. Ronald Kahn, M.D., of Harvard Medical School and the Joslin Diabetes Center, and is detailed in a key 2008 Nature paper outlining the important role of BMP7 in promoting brown fat precursor cells. Dr. Kahn is also a scientific co-founder of Ember.

Back to news